General R&D scope

When the next big advance happens in critical care, we plan to be there

• A rich late-stage pipeline focusing on compounds that are promising in critical care
• iNO: has broad potential in critical care
• Terlipressin and IK-5001: hold great promise
• Continuous investment in exploratory studies in critical care conditions
• Proven execution and support of complex clinical studies in ICU settings
• 4,000 ICU patients studied around the world¹
• Commitment to minimize risk in clinical development through
• Translational medicine
• Adaptive trial design
• Active licensing & acquisition efforts to build on our portfolio